Antivascular therapy for orthotopic human ovarian carcinoma through blockade of the vascular endothelial growth factor and epidermal growth factor receptors

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4923-4933

  Thaker, Premal H ^a   Yazici, Sertac ^a   Nilsson, Monique B ^a   Yokoi, Kenji ^a   Tsan, Rachel Z ^a   He, Junqin ^a   Kim, Sun Jin ^a   Fidler, Isaiah J ^a   Sood, Anil K ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; SODIUM CHLORIDE; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; AUTOPSY; CANCER INHIBITION; CANCER RESISTANCE; CELL LINE; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SENSITIVITY; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; NUDE MOUSE; ORTHOTOPIC TRANSPLANTATION; OVARY CARCINOMA; PERITONEAL CAVITY; PRIORITY JOURNAL; SURVIVAL RATE; TUMOR VOLUME; WESTERN BLOTTING;

ANIMALS; ANTIGENS, CD31; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD VESSELS; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, NUDE; OVARIAN NEOPLASMS; PACLITAXEL; PROLIFERATING CELL NUCLEAR ANTIGEN; PURINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 27644479545     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2060     Document Type: Article

References (50)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-9.
3. du Bois A, Luck H, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003;9:1320-9.
4. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
5. Bookman MA, McGuire WP, Kilpatrick D, et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J Clin Oncol 1996;14:1895-902.
6. Gore ME. Treatment of relapsed epithelial ovarian cancer. In: American Society of Clinical Oncology 2001 education book. Alexandria (VA): American Society of Clinical Oncology; 2001. p. 468-76.
7. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
8. Robinson CJ, Stringer SE. The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 2001;114:853-65.
9. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-5.
10. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
11. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105-15.
12. Paley PJ, Staskus KA, Gebhard K, et al. Vascular endothelial growth factor expression in early stage ovarian carcinoma. Cancer 1997;80:98-106.
13. Cooper BC, Ritchie JM, Broghammer CLW, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res 2002;8:3193-7.
14. Xu L, Yoneda J, Herrera C, Wood J, Killion JJ, Fidler IJ. Inhibition of malignant ascites and growth of human ovarian carcinoma by oral administration of a potent inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Int J Oncol 2000;16:445-54.
15. Morishige K, Kurachi H, Amemiya K, et al. Evidence for the involvement of transforming growth factor α and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991;51:5322-8.
16. Ottensmeier C, Swanson L, Strobel T, Druker B, Niloff J, Cannistra SA. Absence of constitutive EGF receptor activation in ovarian cancer cell lines. Br J Cancer 1996;74;446-52.
17. Bartlett JMS, Langdon SP, Simpson BJB, et al. The prognostic value of epidermal growth factor mRNA expression in primary ovarian cancer. Br J Cancer 1996;73:301-6.
18. Baron AT, Lafky JM, Boardman CH, et al. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Epidemiol Biomarkers Prev 1999;8:129-37.
19. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS, Mok SC. Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 2000;77:369-76.
20. Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated metalloproteinase-9 production and cell surface association. Cancer Res 2001;61:1855-61.
21. Berchuck A, Rodriguez GC, Kamel A, et al. Epidermal growth factor receptor in normal ovarian epithelium and ovarian cancer. Am J Obstet Gynecol 1991;164:669-74.
22. Alper O, Bermann-Leitner ES, Bennett TA, Hacker NF, Stromberg K, Stetler-Stevenson WG. Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells. J Natl Cancer Inst 2001;93:1375-84.
23. Traxler P, Allegrini PR, Brandt R, et al. AEE788: A dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931-41.
24. Buick RN, Pullano R, Trent JM. Comparative properties of five human adenocarcinoma cell lines. Cancer Res 1985;45:3668-76.
25. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 1993:53:891-8.
26. Yoneda J, Kuniyasu H, Crispens MA, Price JE, Bucana CD, Fidler IJ. Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J Natl Cancer Inst 1998;90:447-54.
27. Apte SM, Fan D, Killion JJ, Fidler IJ. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004;10:897-908.
28. b-tsA58 mice for studies of angiogenesis and metastasis. Cancer Res 2003;63:2971-6.
29. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ, Fidler IJ. Blockade of epidermal growth factor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 2003;9:1200-10.
30. Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J Pathol 2002;161:929-38.
31. Maity A, Pore N, Lee J, Solomon D, O'Rourke DM. Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidlyinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 2000;60:5879-86.
32. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
33. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998;273:13313-6.
34. Gerber HP, McMurtrey A, Kowalski J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998;273:30336-43.
35. Tran J, Rak J, Sheehan C, et al. Marked induction of the IAP family antiapoptotic proteins surviving and XIAP by VEGF in vascular endothelial cells. Biochem Biophys Res Commun 1999;264:781-8.
36. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
37. Shimamura A, Ballif BA, Richards SA, Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 2000;10:127-35.
38. Fidler IJ. The organ microenvironment and cancer metastasis (Review). Differentiation 2002;70:498-505.
39. Hobson B, Denekamp J. Endothelial proliferation in tumours and normal tissues: continuous labeling studies. Br J Cancer 1984;49:405-13.
40. Eberhard A, Kahlert S, Goede V, Hemmerlein B, Plate KH, Augustin HG. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Res 2000;60:1388-93.
41. Bocci G, Nicolson KC, Kerbel RS. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 2002;62:6938-43.
42. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
43. Boocock CA, Charnock-Jones S, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. J Natl Cancer Inst 1995;87:506-16.
44. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy-David A. Karnofsky Award Lecture. J Clin Oncol 2002;18:1-13s.
45. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999;13:2905-27.
46. Spyridopoulos I, Brogi E, Kearney M, et al. Vascular endothelial growth factor inhibits endothelial cell apoptosis induced by tumor necrosis factor-α: balance between growth and death signals. J Mol Cell Cardiol 1997;29:1321-30.
47. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
48. Jordan MA, Toso RJ, Thrower D, Wilson L. Mechanism of mitotic blockade and inhibition of cell proliferation by Taxol at low concentrations. Proc Natl Acad Sci U S A 1993;90:9552-6.
49. Fidler IJ. The pathogenesis of cancer metastasis: the "seed and soil" hypothesis revisited (Timeline). Nat Rev Cancer 2003;9:453-8.
50. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.